RESUMO
OBJECTIVE: To explore and describe norms concerning maternity, femininity and cisgender in lesbian and bisexual women and transgender people (LBT) assigned female at birth, with an expressed fear of childbirth (FOC). DESIGN: Semi-structured interviews were conducted with self-identified LBT people with an expressed FOC. PARTICIPANTS: 17 self-identified LBT people participated. 15 had an expressed FOC, and two were non-afraid partners. FINDINGS: Participants described how their FOC was related to ideals of "the primal woman", including ideals of a natural birth. They also described stress in relation to expectations of gaining a feminine-coded body during pregnancy and of being related to as feminine women. KEY CONCLUSIONS: Maternity ideals, and the ideal of the "natural" birth, can be particularly stressful on those who fear childbirth. Norms concerning femininity and cisgender can contribute to FOC among those who do not comfortably conform with feminine body ideals or feminine gender expressions. IMPLICATION FOR PRACTICE: Treatments of FOC must be designed to acknowledge whether and how norms concerning maternity, femininity and cisgender affect the individual's FOC.
Assuntos
Parto Obstétrico/efeitos adversos , Medo/psicologia , Feminilidade , Minorias Sexuais e de Gênero/psicologia , Normas Sociais , Adulto , Parto Obstétrico/psicologia , Feminino , Humanos , Entrevistas como Assunto/métodos , Comportamento Materno/psicologia , Gravidez , Pesquisa Qualitativa , Minorias Sexuais e de Gênero/estatística & dados numéricos , Inquéritos e Questionários , Pessoas Transgênero/psicologia , Pessoas Transgênero/estatística & dados numéricosRESUMO
OBJECTIVE: To explore and describe thoughts about and experiences of pregnancy, childbirth and reproductive healthcare in lesbian and bisexual women and transgender people (LBT) with an expressed fear of childbirth (FOC). DESIGN: Data were collected through semi-structured interviews with self-identified LBTs with an expressed FOC. PARTICIPANTS: 17 self-identified LBTs participated. 15 had an expressed FOC, and two were non-afraid partners. FINDINGS: Participants' fears were similar to those previously described in research on FOC, e.g., fear of pain, injury, blood, death of the child or of the parent. However, minority stress, including fear and experiences of prejudicial treatment, in maternity care and at delivery wards add an additional layer to the fear of childbirth. KEY CONCLUSIONS: LBTs with FOC are a particularly vulnerable group of patients, whose needs must be addressed in healthcare. IMPLICATION FOR PRACTICE: The findings call attention to the need for LBT-competent treatment prior to, and throughout pregnancy and childbirth. In the most vulnerable patients, caregivers must work extensively to build trust, in order to explore and reduce FOC.
Assuntos
Parto Obstétrico/psicologia , Medo , Cuidado Pré-Natal , Minorias Sexuais e de Gênero , Discriminação Social , Adulto , Feminino , Humanos , Entrevistas como Assunto , Gravidez , SuéciaRESUMO
In this work, development of a new microplate-based high-resolution profiling assay using recombinant human aldose reductase is presented. Used together with high-resolution radical scavenging and high-resolution α-glucosidase assays, it provided the first report of a triple aldose reductase/α-glucosidase/radical scavenging high-resolution inhibition profile - allowing proof of concept with Radix Scutellariae crude extract as a polypharmacological herbal drug. The triple bioactivity high-resolution profiles were used to pinpoint bioactive compounds, and subsequent structure elucidation was performed with hyphenated high-performance liquid chromatography-high-resolution mass spectrometry-solid-phase extraction-nuclear magnetic resonance spectroscopy. The only α-glucosidase inhibitor was baicalein, whereas main aldose reductase inhibitors in the crude extract were baicalein and skullcapflavone II, and main radical scavengers were ganhuangemin, viscidulin III, baicalin, oroxylin A 7-O-glucuronide, wogonoside, baicalein, wogonin, and skullcapflavone II.